Introduction
Peptic ulceration, upper gastrointestinal haemorrhage, and gastric and duodenal perforation occur in 400 to 2200 of renal transplant recipients.''-5 The mortality of these conditions is commonly over 500"1 5-7 and may account for 7-50% of all deaths in these patients. 8 Among possible measures for reducing the incidence of these complications prophylactic surgery is difficult to justify. Pretransplant findings correlate poorly with the development of post-transplant gastrointestinal lesions,3 4 6 9 although elective surgery has been recommended in patients awaiting renal transplantation who have peptic ulceration because the incidence of gastrointestinal haemorrhage after transplantation may thereby be reduced.7 An intensive antacid regimen hastens the healing of duodenal ulcer,'0 and there is some evidence that antacids prevent the development of gastric erosions in patients admitted to intensive care units" and in patients with fulminant hepatic failure. ' There is also evidence that, at least in men, renal transplantation is followed by a significant rise in peak acid output. 6 Furthermore, continued damage to the mucosa is probably mediated by mast-cell histamine,2' 22 and raised concentrations in blood and urine have been shown after renal transplantation.2' We therefore decided to assess the place of a histamine H2-receptor antagonist cimetidine in the management of patients undergoing renal transplantation.
Patients and methods
Thirty-five consecutive patients who received cimetidine after transplantation were studied prospectively. The incidence of gastrointestinal haemorrhage was compared with that in the previous 35 transplant recipients, who had not received cimetidine.
Three of the treated patients died in the first week after transplantation (two from myocardial infarction and one from anaphylactic reaction to antilymphocyte globulin) and two developed generalised mucosal haemorrhage due to septicaemia and proved coagulopathy. One untreated patient died 24 hours after operation, and another died from generalised mucosal bleeding due to pancreatitis, septicaemia, and coagulopathy. These seven patients were excluded from further analysis, leaving a total of 63 (table I) .
There was no significant difference between the groups in the numbers of patients with delayed graft function or the occurrence of post-transplant problems such as septicaemia, acute rejection, and surgical complications. Patient survival at four months was 700% in each group, and of those that died, about 25 % in each group died with a functioning transplant.
The renal transplants were performed by two surgeons in the same unit over 17 months. Immediately after transplantation all patients received the following immunosuppressive regimen: (a) prednisone or prednisolone (or hydrocortisone equivalent) was given in a dose of 200 mg/day for three days, 150 mg/day for three days, 100 mg/day for three days, and reducing to a dose of about 20-25 mg/day at four months; (b) daily azathioprine was given in a dose of 2 mg/kg/day adjusted according to the white blood cell and platelet counts; (c) antilymphocyte globulin was given to 10 patients in the untreated group and 13 in the treated group; (d) acute rejection was treated with intravenous doses of 1 g methylprednisolone on three successive days atigmented, when necessary, by a three-day course of actinomycin D and radiotherapy.
Cimetidine was given immediately the patient returned from the theatre, and the starting dose for all patients was 200 mg intravenously every 12 hours; this regimen was continued orally when appropriate. When renal function began to improve the dose was increased to 200 mg every eight hours and to the more usual regimen of 200 mg thrice daily and 400 mg at night when the serum creatinine concentration fell below 300 Lmol/l (3 4 mg/100 ml). All patients received cimetidine for four to six weeks apart from two patients who left hospital within a fortnight of the transplant. Two patients with newly diagnosed duodenal ulceration were treated with cimetidine for three weeks before transplantation.
Patients receiving cimetidine did not routinely receive antacids. The untreated patients were given aluminium hydroxide suspension (Aludrox) 10-20 ml every four hours, changing to 7 50% aluminium 
Discussion
There is a striking difference between the incidence of and morbidity and mortality from peptic ulceration before and after renal transplantation.6 Early reports of a high incidence of peptic ulcer disea6e in uraemic patients24 25 are suspect because the diagnostic criteria were unreliable.26 The incidence is probably no greater than that found in age-matched controls among the general population.6 2 28 After renal transplantation, however, the incidence of peptic ulcer disease may be as high as 22 0 6; moreover, gastrointestinal haemorrhage from these lesions carries a high mortality, often over 50O0.15-' We have shown here that cimetidine, routinely administered after renal transplantation, significantly reduces the incidence of gastrointestinal haemorrhage.
Upper gastrointestinal complications of transplantation may occur years after the transplant but most occur within the first four months. 6 7 Haemorrhage is the commonest complication and occurs from gastric, oesophageal, or duodenal erosions in the first week or so, when immunosuppression is maximal, and later from similar lesions in patients who become seriously ill from sepsis, rejection and its treatment, and surgical or other complications. A third group of patients develop more localised peptic ulceration, usually pyloric or duodenal, after about six weeks. Bleeding from a single gastric ulcer after transplantation is distinctly uncommon.2 6 Our experience corresponds with this (see table III).
Since the presence of gastric acid is of central importance in the pathogenesis of these lesions," ' reduction in gastric acid secretion might be expected to influence their development, and the possible role of histamine2-23 as a mediator of mucosal injury reinforces the rationale for using an H 2-receptor antagonist. Cimetidine has been shown to be effective in preventing acute upper gastrointestinal haemorrhage in fulminant hepatic failure"3; so long as intragastric pH was maintained above 5 bleeding was almost totally eliminated. The therapeutic role of cimetidine in duodenal ulceration is established, 1 19 and recent reports show that it also hastens the healing of benign gastric ulcers.20 The increase in mean peak acid output after renal transplantation, however, is significantly increased in men but not in women.6 None the less, half of our patients who developed upper gastrointestinal haemorrhage, 33°%, of those in the study of Chisholm et al (1977) , and 44°,, of those in the study of Hadjiyannakis et al (1971) were women, which suggests that other factors play a part.
It has been suggested that administration of corticosteroids may damage the gastric mucosa29 or impair the resistance of the mucosal barrier to injury.3 A significantly higher incidence of peptic ulceration was observed in a large series of patients with rheumatoid arthritis treated with steroids,2 and the recent findings of McGeown et al (1977) in renal transplant recipients reinforces this view. With a starting dose of prednisone of only 20 mg day after transplantation only one out of 100 patients died from upper gastrointestinal haemorrhage.
The treated and untreated groups were well matched for age, sex, and blood group and the immunosuppressive regimen was standardised throughout the study. The high incidence (180,) of gastrointestinal haemorrhage in the untreated group may reflect the steroid dosage used. No other symptomatic upper gastrointestinal tract complications occurred in either group, however, which compares favourably with the results in other series, in which symptomatic peptic ulceration has occurred in up to 2200 of patients.6 The overall mortality in the untreated group was low at 3%0, and among those who bled, the mortality was only 16O-.
None of the patients who had previously diagnosed (and medically treated) peptic ulceration but did not receive cimetidine bled, but the patient with giant rugal hypertrophy died from his gastrointestinal haemorrhage. The endoscopic confirmation of healing in the patients in the treated group who were known to have active lesions shortly before transplantation is encouraging, and cimetidine may have a therapeutic as well as prophylactic part to play in managing established peptic ulceration in transplant recipients.
Cimetidine is excreted by the kidneys; in the presence of delayed graft function 200 mg of cimetidine given every 12 hours will produce therapeutic blood concentrations until renal function begins to improve.30 The drug appears to be compl^tely cleared by haemodialysis.'0 Recent reportso' 32 Of central nervous system and other side effects (mental confusion, agitation, flushing, and sweating), possibly related to overdose, are worrying, but none were observed in our patients. No other adverse effects attributable to the drug were observed, either clinically or in terms of haematological or biochemical values.
